Company intelligence / Profile preview
FundaMental Pharma
Heidelberg, Baden-Württemberg, Germanyfundamentalpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
FundaMental Pharma has developed first-in-class small molecule inhibitors that selectively block the toxic effects of extrasynaptic NMDARs while preserving their physiological function. These candidates are currently in preclinical development with plans to enter human trials within 2–3 years. The approach aims to halt neurodegeneration and restore brain health by eliminating glutamate excitotoxicity without impairing normal neuronal activity
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on FundaMental Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FundaMental Pharma.